Shots:
- Bio-Thera and Intas Pharmaceuticals have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab) in the US
- As per the agreement, Bio-Thera is entitled to receive $21M upfront and an additional $143.5M in development and commercial milestones
- BAT2506 is an IgG1 monoclonal antibody targeting TNF-alpha, reducing inflammatory markers like CRP, IL-6, ICAM-1, MMP-3, and VEGF. The reference medicine is approved in US and Europe for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis
Ref: Prnewswire | Image: Bio-Thera & Intas Pharmaceuticals
Related News:- Bio-Thera Reports the EMA’s MAA Acceptance of BAT2506 (Biosimilar, Simponi)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
